AVTX

Avalo Therapeutics, Inc. (AVTX) | Rumor.io

Avalo Therapeutics

AVTX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,717

Bullish sentiment (50-day avg)87%

Price to earnings ratio2.3

Market capitalization808.7M

Earnings per share-4.41

Dividend yield (TTM)—

Revenue (annual)59K

Net income (annual)-78.3M

Social

What share of all stock conversation is about AVTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 17

Avalo Therapeutics, Inc. ($AVTX) has a market cap of around $130 million.
The company's stock has been experiencing volatility, with some analysts predicting a potential surge in price.
Avalo Therapeutics is working on developing treatments for cancer and other diseases, with a focus on precision medicine.

Generated by AI

Sentiment

Of the messages about AVTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +25	82.62% -2.58
Bearish	0%	0%	0% -25	17.38% +2.58

Bullish· May 6

$AVTX's positive topline results in the Phase 2 LOTUS trial of Abdakibart, with consistent responses across both doses vs main comp Luti in HiSCR75 (and HiSCR50 too), justify the stock move.
BTIG raised the firm's price target on Avalo Therapeutics to $58 from $40, citing the company's announcement of positive topline results in the Phase 2 LOTUS trial, and maintains a Buy rating on the shares.
The company's recent 375M offering at $17.75 is seen as necessary for Phase 3, and with 21% short interest, it could easily squeeze to 30+ but for tomorrow 30+ push won't happen.

Bearish· May 6

$AVTX's recent 48% surge may be unsustainable due to its over-extended position with only phase 2 data.
The company's massive $375M offering at $17.75 may lead to short-term price settling around $20-$21.
$AVTX's high market cap ($1B+) and phase 2 data may make it an attractive takeover candidate, potentially leading to a sharp price drop.

Generated by AI

Topics

Of the messages about AVTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	71.65%
Technical Analysis	—	—	0%	18.3%
Earnings	—	—	0%	0.67%
Analysts	—	—	50%	7.38%
Controversies	—	—	0%	1.92%
Macro	—	—	0%	0.1%

Earnings· Nov 9

Avalo Therapeutics ($AVTX) reported Q3 earnings, beating estimates by 90% with an EPS of $-0.11 vs an estimated loss of $-1.1.
The company's reported loss of $-0.11 was significantly better than the expected loss of $-1.10.
The earnings beat was considered a "monster beat" and was seen as a positive surprise, with many analysts and investors expressing enthusiasm for the results.

Announcements· May 6

Avalo Therapeutics has announced positive topline results in the Phase 2 LOTUS trial of abdakibart for moderate-to-severe hidradenitis suppurativa, with the trial hitting HiSCR75 at Week 16 in both dose groups vs placebo.
BTIG has raised its price target on Avalo Therapeutics to $58 from $40 and maintains a Buy rating on the shares, citing the company's announcement of positive trial results.
Avalo Therapeutics has priced a $375 million public offering of common stock and pre-funded warrants at $17.75 per share, which will be used to secure enough money to deliver topline Phase 3 data.

Technical Analysis· Apr 1

$AVTX has broken through support at $20 and is holding a support zone at $15.5.
The 1-hour chart is showing a strong upward trend, with a bullish doji candle.
The stock is overbought with an RSI of 92.24%, and may be due for a pullback or a squeeze in a stock with a low share float, such as $BDRX.

Generated by AI

Community

Of the messages about AVTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.24%	79.07%	53.83%
Newcomers	0%	11.76%	20.93%	46.17%

Regulars· Aug 17

The regulars are watching the stock closely, with one mention of a price alert and another mentioning a potential trading opportunity.
The price of $AVTX is expected to increase tomorrow, according to one of the regulars.
Another regular is speculating about the potential impact of a recent news article on the stock's price.

Newcomers· May 8

The newcomers are enthusiastic about the stock picks and daily profits they're earning from following these experts, with some even claiming to have "banked great profits" or earned "excellent profits".
The experts being followed are recommended for their ability to find "winners that pump quick" or "picks that rise almost daily", with some even suggesting that following them is a way to avoid "gambling" and start making consistent profits.
The newcomers are impressed by the daily gains and are eager to start following these experts to earn better profits, with some even suggesting that their portfolios "need" this expertise.

Generated by AI

News

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX)

25d agoSeeking Alpha

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as

26d agoYahoo Finance

Also Discussed

Investors talking about AVTX also mention

#	Name	Attention
1	NVOS - Novo Integrated Sciences, Inc.	——
2	AXLA - Axcella Health Inc.	——
3	EBET - EBET, Inc.	——
4	T2 Biosystems, Inc.TTOO	0%new
5	LMDX - LumiraDx Limited	——
6	ZVSA - ZyVersa Therapeutics, Inc.	——
7	Femasys Inc.FEMY	0%+0
8	NFTG - The NFT Gaming Company, Inc.	——
9	Tempest Therapeutics Inc.TPST	0%+0
10	AWIN - AERWINS Technologies Inc.	——

Avalo Therapeutics, Inc.

Healthcare
Biotechnology

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions. Avalo Therapeutics also maintains a pipeline that includes additional immune-focused programs, reflecting its emphasis on targeting dysregulated inflammation through biologic therapies. Based in Wayne, Pennsylvania, and incorporated in 2011, the company operates within the immunology and inflammation space, where its products are aimed at diseases with significant unmet medical need.

Website

Location

540 Gaither Road

Rockville, MD, 20850

United States

Social

What share of all stock conversation is about AVTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% +0

Aug 17

Avalo Therapeutics, Inc. ($AVTX) has a market cap of around $130 million.
The company's stock has been experiencing volatility, with some analysts predicting a potential surge in price.
Avalo Therapeutics is working on developing treatments for cancer and other diseases, with a focus on precision medicine.

Generated by AI

Sentiment

Of the messages about AVTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +25	82.62% -2.58
Bearish	0%	0%	0% -25	17.38% +2.58

Bullish· May 6

$AVTX's positive topline results in the Phase 2 LOTUS trial of Abdakibart, with consistent responses across both doses vs main comp Luti in HiSCR75 (and HiSCR50 too), justify the stock move.
BTIG raised the firm's price target on Avalo Therapeutics to $58 from $40, citing the company's announcement of positive topline results in the Phase 2 LOTUS trial, and maintains a Buy rating on the shares.
The company's recent 375M offering at $17.75 is seen as necessary for Phase 3, and with 21% short interest, it could easily squeeze to 30+ but for tomorrow 30+ push won't happen.

Bearish· May 6

$AVTX's recent 48% surge may be unsustainable due to its over-extended position with only phase 2 data.
The company's massive $375M offering at $17.75 may lead to short-term price settling around $20-$21.
$AVTX's high market cap ($1B+) and phase 2 data may make it an attractive takeover candidate, potentially leading to a sharp price drop.

Generated by AI

Topics

Of the messages about AVTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	71.65%
Technical Analysis	—	—	0%	18.3%
Earnings	—	—	0%	0.67%
Analysts	—	—	50%	7.38%
Controversies	—	—	0%	1.92%
Macro	—	—	0%	0.1%

Earnings· Nov 9

Avalo Therapeutics ($AVTX) reported Q3 earnings, beating estimates by 90% with an EPS of $-0.11 vs an estimated loss of $-1.1.
The company's reported loss of $-0.11 was significantly better than the expected loss of $-1.10.
The earnings beat was considered a "monster beat" and was seen as a positive surprise, with many analysts and investors expressing enthusiasm for the results.

Announcements· May 6

Avalo Therapeutics has announced positive topline results in the Phase 2 LOTUS trial of abdakibart for moderate-to-severe hidradenitis suppurativa, with the trial hitting HiSCR75 at Week 16 in both dose groups vs placebo.
BTIG has raised its price target on Avalo Therapeutics to $58 from $40 and maintains a Buy rating on the shares, citing the company's announcement of positive trial results.
Avalo Therapeutics has priced a $375 million public offering of common stock and pre-funded warrants at $17.75 per share, which will be used to secure enough money to deliver topline Phase 3 data.

Technical Analysis· Apr 1

$AVTX has broken through support at $20 and is holding a support zone at $15.5.
The 1-hour chart is showing a strong upward trend, with a bullish doji candle.
The stock is overbought with an RSI of 92.24%, and may be due for a pullback or a squeeze in a stock with a low share float, such as $BDRX.

Generated by AI

Community

Of the messages about AVTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	88.24%	79.07%	53.83%
Newcomers	0%	11.76%	20.93%	46.17%

Regulars· Aug 17

The regulars are watching the stock closely, with one mention of a price alert and another mentioning a potential trading opportunity.
The price of $AVTX is expected to increase tomorrow, according to one of the regulars.
Another regular is speculating about the potential impact of a recent news article on the stock's price.

Newcomers· May 8

The newcomers are enthusiastic about the stock picks and daily profits they're earning from following these experts, with some even claiming to have "banked great profits" or earned "excellent profits".
The experts being followed are recommended for their ability to find "winners that pump quick" or "picks that rise almost daily", with some even suggesting that following them is a way to avoid "gambling" and start making consistent profits.
The newcomers are impressed by the daily gains and are eager to start following these experts to earn better profits, with some even suggesting that their portfolios "need" this expertise.

Generated by AI

Avalo Therapeutics

Social

Aug 17

Bullish· May 6

Bearish· May 6

Earnings· Nov 9

Announcements· May 6

Technical Analysis· Apr 1

Regulars· Aug 17

Newcomers· May 8

Avalo Therapeutics at Stifel forum: hs push gains traction

Avalo Therapeutics at H.C. Wainwright conference: phase 2 data lift outlook

Cantor Fitzgerald reiterates Avalo Therapeutics stock rating

Avalo Therapeutics at Cantor conference: building around il-1 beta

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX)

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Avalo Therapeutics, Inc.

Company Information

Location

Avalo Therapeutics at Stifel forum: hs push gains traction

Avalo Therapeutics at H.C. Wainwright conference: phase 2 data lift outlook

Cantor Fitzgerald reiterates Avalo Therapeutics stock rating

Avalo Therapeutics at Cantor conference: building around il-1 beta

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX)

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Social

Aug 17

Bullish· May 6

Bearish· May 6

Earnings· Nov 9

Announcements· May 6

Technical Analysis· Apr 1

Regulars· Aug 17

Newcomers· May 8